Latest BridgeBio data support acoramidis benefit in ATTR-CM

2024-05-30

交易

临床结果临床3期上市批准AHA会议

BridgeBio Pharma announced on Thursday that acoramidis increased serum transthyretin (TTR), which is associated with improved cardiovascular outcomes, in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The latest data from a Phase III ATTRibute-CM study were presented at the International Symposium of Amyloidosis (ISA).

A filing for the small-molecule, orally-administered TTR stabiliser is under review in the US, with the FDA set to make a decision by November 29. Earlier this year, Bayer gained exclusive rights to commercialise acoramidis in Europe pending approval in the region. Both the marketing applications are based on findings from the study in which acoramidis demonstrated an 81% absolute survival rate in patients who received the treatment, and a mean annual frequency of 0.29 for cardiovascular-related hospitalisations.

The latest data confirmed the correlation between increased serum TTR and improved clinical outcomes, including the reduced risk of all-cause mortality (ACM) and cardiovascular mortatlity (CVM) as well as cardiovascular-related hospitalisation (CRH). Acoramidis treatment resulted in increased serum TTR levels by day 28 that were sustained and correlated with a reduced risk of all- ACM by as much as 51%, CVM by 5.5% and CVH by 4.7% through month 30. Acoramidis treatment resulted in a significant improvement in the composite endpoint of CVM and CVH, with a 15.2% absolute risk reduction and a 38.2% hazard reduction by month 30.

"We remain encouraged by the potential benefits of targeting near-complete TTR stabilisation, the resulting increases in serum TTR, and the corresponding statistically significant benefits on clinical event outcomes," said chief medical officer Jonathan Fox. "We are committed to bringing acoramidis to the ATTR-CM community as quickly as possible, working toward our November 29 PDUFA date."

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构